Ccne1 (cyclin E1) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Ccne1 (cyclin E1) Rattus norvegicus
Analyze
Symbol: Ccne1
Name: cyclin E1
RGD ID: 2294
Description: Enables protein kinase binding activity. Involved in several processes, including response to corticosterone; response to progesterone; and response to vitamin E. Located in centrosome. Biomarker of hepatocellular carcinoma; hypertension; liver cancer; and ovarian carcinoma. Human ortholog(s) of this gene implicated in breast adenocarcinoma. Orthologous to human CCNE1 (cyclin E1); PARTICIPATES IN G1/S transition pathway; mTOR signaling pathway; cell cycle pathway, mitotic; INTERACTS WITH (-)-citrinin; (Z)-3-butylidenephthalide; 1,3-dichloropropan-2-ol.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: Ccne; CYCLE; cyclin E; G1/S-specific cyclin-E1
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8199,918,672 - 99,927,986 (-)NCBIGRCr8
mRatBN7.2190,781,947 - 90,791,188 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl190,781,949 - 90,791,101 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx196,177,587 - 96,186,820 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01104,643,512 - 104,652,745 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0197,935,949 - 97,945,186 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0194,485,830 - 94,495,112 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl194,485,832 - 94,494,980 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0195,575,136 - 95,584,387 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4190,568,189 - 90,577,426 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1190,646,304 - 90,655,502 (-)NCBI
Celera185,114,968 - 85,124,206 (-)NCBICelera
RH 3.4 Map1885.7RGD
Cytogenetic Map1q21NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-citrinin  (EXP,ISO)
(-)-demecolcine  (ISO)
(S)-naringenin  (ISO)
(S)-nicotine  (ISO)
(Z)-3-butylidenephthalide  (EXP,ISO)
1,3-dichloropropan-2-ol  (EXP)
1-(4-methoxybenzyl)-3-(5-nitro-1,3-thiazol-2-yl)urea  (ISO)
1-chloro-2,4-dinitrobenzene  (ISO)
1-naphthyl isothiocyanate  (EXP)
14-Deoxy-11,12-didehydroandrographolide  (ISO)
15-deoxy-Delta(12,14)-prostaglandin J2  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
19-Nor-17alpha-pregn-5(10)-en-20-yne-3alpha,17beta-diol  (EXP)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,6-di-tert-butyl-4-methylphenol  (ISO)
2,6-dinitrotoluene  (EXP)
2-acetamidofluorene  (EXP)
2-butoxyethanol  (ISO)
2-hydroxypropanoic acid  (ISO)
2-trans,6-trans,10-trans-geranylgeranyl diphosphate  (EXP)
3,3',4,4'-tetrachlorobiphenyl  (ISO)
3,3',5-triiodo-L-thyronine  (EXP,ISO)
3,7-dihydropurine-6-thione  (EXP)
3-[(4-anilinophenyl)diazenyl]benzene-1-sulfonic acid  (EXP)
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid  (ISO)
3-chloropropane-1,2-diol  (EXP)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3-methyladenine  (ISO)
3-methylcholanthrene  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-(ethoxymethylene)-2-phenyloxazol-5-one  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
4-nitrophenol  (ISO)
4-nonylphenol  (ISO)
5,7-dihydroxy-4'-methoxyflavone  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-fluorouracil  (ISO)
5-formyltetrahydrofolic acid  (ISO)
5-methoxypsoralen  (ISO)
6-Methoxyflavone  (ISO)
6-propyl-2-thiouracil  (EXP)
9-Methoxycamptothecin  (ISO)
acetamide  (EXP)
acetylsalicylic acid  (EXP,ISO)
acrylamide  (EXP,ISO)
acrylonitrile  (ISO)
acteoside  (ISO)
afimoxifene  (ISO)
aflatoxin B1  (EXP,ISO)
aldehydo-D-glucose  (EXP)
all-trans-retinoic acid  (EXP,ISO)
allose  (ISO)
alpha-amanitin  (ISO)
alvocidib  (ISO)
amitrole  (EXP)
amlodipine  (ISO)
ammonium chloride  (EXP)
amsacrine  (ISO)
andrographolide  (ISO)
androstane  (ISO)
aniline  (EXP)
antroquinonol  (ISO)
arotinoid acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
artesunate  (EXP)
Aspidin  (ISO)
atrazine  (ISO)
atropine  (ISO)
baicalein  (EXP,ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
benzoates  (ISO)
berberine  (ISO)
bexarotene  (ISO)
bifenthrin  (EXP)
biotin  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisphenol A  (EXP,ISO)
Bisphenol A diglycidyl ether  (ISO)
bisphenol F  (ISO)
BKM120  (EXP)
brassinolide  (ISO)
bromobenzene  (EXP)
budesonide  (ISO)
Butylparaben  (ISO)
butyric acid  (EXP)
C.I. Natural Red 20  (EXP)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
caffeine  (ISO)
calciol  (ISO)
camostat  (ISO)
camptothecin  (ISO)
cannabidiol  (ISO)
carbamazepine  (ISO)
carbon nanotube  (ISO)
Cardanol  (ISO)
carmustine  (EXP)
cefaloridine  (EXP)
CGP 52608  (ISO)
chlorohydrocarbon  (ISO)
chlorpyrifos  (ISO)
choline  (EXP,ISO)
chromium(6+)  (ISO)
ciprofloxacin  (ISO)
cisplatin  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) chloride  (ISO)
copper(II) sulfate  (ISO)
cordycepin  (EXP,ISO)
corticosterone  (EXP)
coumarin  (EXP,ISO)
coumestrol  (ISO)
crocidolite asbestos  (ISO)
Cuprizon  (EXP)
curcumin  (EXP,ISO)
Cyclopamine  (ISO)
cyclosporin A  (ISO)
cyprodinil  (ISO)
D-glucose  (EXP)
daunorubicin  (ISO)
deguelin  (ISO)
deoxynivalenol  (ISO)
desferrioxamine B  (ISO)
dexamethasone  (ISO)
diarsenic trioxide  (ISO)
diazinon  (EXP)
dibutyl phthalate  (ISO)
dichloroacetic acid  (ISO)
diclofenac  (ISO)
dieckol  (ISO)
dieldrin  (EXP)
diethanolamine  (EXP,ISO)
diethylstilbestrol  (ISO)
Dinitramine  (ISO)
dioscin  (ISO)
dioxygen  (ISO)
disodium selenite  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
EHT 1864  (ISO)
entinostat  (ISO)
epoxiconazole  (ISO)
estragole  (EXP,ISO)
estriol  (ISO)
ethanol  (ISO)
ethidium  (ISO)
fenhexamid  (ISO)
flavanones  (ISO)
fludioxonil  (ISO)
flumequine  (ISO)
fluoxetine  (ISO)
folic acid  (ISO)
FR900359  (ISO)
fraxetin  (ISO)
fulvestrant  (ISO)
furan  (EXP)
gadolinium trichloride  (ISO)
gallic acid  (ISO)
gamma-linolenic acid  (ISO)
gamma-tocopherol  (ISO)
genistein  (EXP,ISO)
gentamycin  (EXP)
gingerol  (ISO)
ginsenoside Rg1  (ISO)
glucose  (EXP)
glyphosate  (ISO)
GW 3965  (ISO)
GW 4064  (ISO)
hexachlorobenzene  (ISO)
hydrogen chloride  (ISO)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
hydroxyurea  (ISO)
Hypsiziprenol-A9  (ISO)
indole-3-methanol  (ISO)
indometacin  (EXP)
inulin  (ISO)
iodoacetic acid  (ISO)
Isoliensinine  (ISO)
isoprene  (ISO)
isosilybin A  (ISO)
kainic acid  (EXP)
lactacystin  (ISO)
lapatinib  (ISO)
lead diacetate  (ISO)
Licochalcone B  (ISO)
lidocaine  (ISO)
LY294002  (ISO)
lycopene  (ISO)
magnesium atom  (EXP)
malachite green cation  (EXP)
malathion  (ISO)
manganese atom  (ISO)
manganese(0)  (ISO)
manganese(II) chloride  (ISO)
MeIQx  (ISO)
melatonin  (ISO)
menadione  (ISO)
mercaptopurine  (EXP)
metformin  (EXP,ISO)
methamphetamine  (EXP)
methimazole  (EXP)
methotrexate  (EXP,ISO)
methoxyacetic acid  (EXP)
methoxychlor  (EXP)
methyl isocyanate  (ISO)
methylarsonic acid  (EXP)
methylisothiazolinone  (ISO)
methylmercury chloride  (EXP)
methylparaben  (ISO)
mevalonic acid  (EXP)
mifepristone  (ISO)
ML-7  (EXP)
mono(2-ethylhexyl) phthalate  (ISO)
monobenzyl phthalate  (ISO)
monoethyl phthalate  (ISO)
N-(6-acetamidohexyl)acetamide  (ISO)
N-acetyl-L-cysteine  (EXP,ISO)
N-nitrosodiethylamine  (EXP,ISO)
naringin  (EXP,ISO)
nickel atom  (ISO)
nickel dichloride  (EXP)
niclosamide  (ISO)
nicotine  (ISO)
nitrofurazone  (EXP)
Nonylphenol  (EXP,ISO)
ochratoxin A  (EXP,ISO)
olaparib  (ISO)
oleanolic acid  (ISO)
oligomycin A  (ISO)
omacetaxine mepesuccinate  (ISO)
orlistat  (ISO)
oxaliplatin  (EXP,ISO)
ozone  (EXP,ISO)
paclitaxel  (ISO)
palbociclib  (ISO)
Panduratin A  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
parathion  (ISO)
PCB138  (ISO)
PD 0325901  (ISO)
pentachlorophenol  (EXP)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
phenethyl caffeate  (EXP,ISO)
phenethyl isothiocyanate  (ISO)
phenobarbital  (EXP)
phenytoin  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
phosphatidylcholine  (ISO)
pinostrobin  (ISO)
pinosylvin  (ISO)
pioglitazone  (ISO)
pirinixic acid  (EXP,ISO)
procymidone  (EXP)
progesterone  (ISO)
propylparaben  (ISO)
pterostilbene  (EXP)
purine-6-thiol  (EXP)
pyrrolidine dithiocarbamate  (EXP)
quercetin  (ISO)
rac-lactic acid  (ISO)
resveratrol  (EXP,ISO)
retinyl acetate  (ISO)
ribavirin  (ISO)
Ro 41-5253  (ISO)
rubitecan  (ISO)
Sanggenon C  (ISO)
SB 431542  (ISO)
Shikonin  (EXP)
silibinin  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
silver(1+) nitrate  (ISO)
simvastatin  (EXP)
sirolimus  (ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (EXP)
sorafenib  (ISO)
spiromesifen  (ISO)
sulfadimethoxine  (EXP)
sulforaphane  (ISO)
sulindac  (ISO)
sunitinib  (ISO)
taiwanin C  (ISO)
tamoxifen  (EXP,ISO)
taurocholic acid  (ISO)
teriflunomide  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (ISO)
tetracaine  (ISO)
tetrachloromethane  (ISO)
thioacetamide  (EXP)
thiram  (ISO)
thymoquinone  (EXP)
tioguanine  (EXP)
titanium dioxide  (EXP,ISO)
tocopherol  (ISO)
toluene 2,4-diisocyanate  (ISO)
Tomentosin  (ISO)
topotecan  (EXP,ISO)
trabectedin  (ISO)
trans-pinosylvin  (ISO)
trichostatin A  (ISO)
trimellitic anhydride  (ISO)
trimethylarsine oxide  (EXP)
Triptolide  (ISO)
troglitazone  (ISO)
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate  (ISO)
tungsten  (ISO)
tyrphostin AG 1478  (ISO)
ursolic acid  (ISO)
valproic acid  (ISO)
vemurafenib  (ISO)
vinclozolin  (EXP,ISO)
vincristine  (ISO)
vitamin E  (EXP)
vorinostat  (ISO)
wortmannin  (ISO)
zearalenone  (ISO)
zinc atom  (ISO)
zinc(0)  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

References

References - curated
# Reference Title Reference Citation
1. Integrated profiling of basal and luminal breast cancers. Adelaide J, etal., Cancer Res. 2007 Dec 15;67(24):11565-75.
2. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Akli S, etal., Cancer Res. 2007 Aug 1;67(15):7212-22.
3. The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. Bahnassy AA, etal., J Egypt Natl Canc Inst. 2006 Dec;18(4):292-302.
4. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. Berglund P, etal., J Clin Pathol. 2007 May 4;.
5. Alcohol linked to enhanced angiogenesis in rat model of choroidal neovascularization. Bora PS, etal., FEBS J. 2006 Apr;273(7):1403-14.
6. D-type cyclins and G1 progression during liver development in the rat. Boylan JM and Gruppuso PA, Biochem Biophys Res Commun. 2005 May 13;330(3):722-30.
7. Methylmercury elicits rapid inhibition of cell proliferation in the developing brain and decreases cell cycle regulator, cyclin E. Burke K, etal., Neurotoxicology. 2006 Dec;27(6):970-81. Epub 2006 Sep 15.
8. Granulosa cell expression of G1/S phase cyclins and cyclin-dependent kinases in PMSG-induced follicle growth. Cannon JD, etal., Mol Cell Endocrinol. 2007 Jan 29;264(1-2):6-15. Epub 2006 Nov 7.
9. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. Chanal M, etal., Mol Cancer Ther. 2016 Jun;15(6):1261-70. doi: 10.1158/1535-7163.MCT-15-0891. Epub 2016 Mar 16.
10. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Christov K, etal., Breast Cancer Res Treat. 2003 Feb;77(3):253-64.
11. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Davidson B, etal., Cancer. 2007 Sep 15;110(6):1264-71.
12. Differential and combined effects of cardiotrophin-1 and TGF-beta1 on cardiac myofibroblast proliferation and contraction. Drobic V, etal., Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1053-64. Epub 2007 May 4.
13. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Eder AM, etal., Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12519-24. Epub 2005 Aug 22.
14. Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury. Ehedego H, etal., Oncogene. 2018 Jun;37(25):3329-3339. doi: 10.1038/s41388-018-0181-8. Epub 2018 Mar 19.
15. Parallel cyclin E and cyclin A expression in neoplastic lesions of the uterine cervix. Erlandsson F, etal., Br J Cancer. 2006 Apr 10;94(7):1045-50.
16. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
17. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
18. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. Horree N, etal., J Clin Pathol. 2008 Jan;61(1):36-42. Epub 2007 May 4.
19. Overexpression of cyclin D1 and cyclin E in 1,2-dimethylhydrazine dihydrochloride-induced rat colon carcinogenesis. Hur K, etal., J Vet Sci. 2000 Dec;1(2):121-6.
20. Nitrofurazone-induced gene expressions in rat hepatocytes and their modification by N-acetylcysteine. Ito K, etal., Exp Toxicol Pathol. 2005 Apr;56(6):333-9.
21. Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats. Jiang W, etal., Cancer Res. 2003 Mar 15;63(6):1228-34.
22. Hesperetin, a bioflavonoid, inhibits rat aortic vascular smooth muscle cells proliferation by arresting cell cycle. Jin YR, etal., J Cell Biochem. 2007 Nov 2;.
23. Quantitative analysis of cyclin E and protein p34 cdc2 expression in superficial bladder cancer. Kaczmarek P, etal., Pol J Pathol. 2006;57(1):41-4.
24. ATP-dependent activation of p21WAF1/CIP1-associated Cdk2 by Cdc6. Kan Q, etal., Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4757-62. doi: 10.1073/pnas.0706392105. Epub 2008 Mar 20.
25. Overexpression of p21, cyclin E and decreased expression of p27 in DMBA (7, 12-dimethylbenzanthracene)-induced rat ovarian carcinogenesis. Kim KK, etal., Pathol Int. 2003 May;53(5):291-6.
26. Dehydroepiandrosterone causes hyperplasia and impairs regeneration in rat liver. Kopplow K, etal., Int J Oncol. 2005 Dec;27(6):1551-8.
27. Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways. Korashy HM, etal., Anticancer Res. 2017 Sep;37(9):4899-4909. doi: 10.21873/anticanres.11899.
28. Long-term 17alpha-ethinyl estradiol treatment decreases cyclin E and cdk2 expression, reduces cdk2 kinase activity and inhibits S phase entry in regenerating rat liver. Koroxenidou L, etal., J Hepatol. 2005 Sep;43(3):478-84.
29. High-density rat radiation hybrid maps containing over 24,000 SSLPs, genes, and ESTs provide a direct link to the rat genome sequence. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7
30. Molecular mechanism of progesterone-induced antiproliferation in rat aortic smooth muscle cells. Lee WS, etal., Endocrinology. 2003 Jul;144(7):2785-90.
31. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Maddison LA, etal., Prostate. 2004 Mar 1;58(4):335-44.
32. Mammalian cyclin-dependent kinases. Malumbres M and Barbacid M, Trends Biochem Sci. 2005 Nov;30(11):630-41. Epub 2005 Oct 19.
33. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Matsumoto Y and Maller JL, Science. 2004 Oct 29;306(5697):885-8.
34. Cell-cycle inhibition by TNP-470 in an in vivo model of hepatocarcinoma is mediated by a p53 and p21WAF1/CIP1 mechanism. Mauriz JL, etal., Transl Res. 2007 Jan;149(1):46-53.
35. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
36. Vitamin E deficiency induces liver nuclear factor-kappaB DNA-binding activity and changes in related genes. Morante M, etal., Free Radic Res. 2005 Oct;39(10):1127-38.
37. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Müller-Tidow C, etal., Cancer Res. 2001 Jan 15;61(2):647-53.
38. Elevated cyclin E level in human clear cell renal cell carcinoma: possible causes and consequences. Nauman A, etal., Acta Biochim Pol. 2007;54(3):595-602. Epub 2007 Aug 28.
39. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
40. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
41. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
42. Differential association of p21Cip1 and p27Kip1 with cyclin E-CDK2 during rat liver regeneration. Pujol MJ, etal., J Hepatol. 2000 Aug;33(2):266-74.
43. Reactome: A Knowledgebase of Biological Processes Reactome
44. Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway. Ren S, etal., Int J Biochem Cell Biol. 2020 Aug;125:105777. doi: 10.1016/j.biocel.2020.105777. Epub 2020 Jun 3.
45. GOA pipeline RGD automated data pipeline
46. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
47. Stimulation of a rat uterine stromal cell line in culture reveals a molecular switch for endocrine-dependent differentiation. Rider V, etal., J Endocrinol. 2005 Jan;184(1):119-27.
48. Di(2-ethylhexyl) phthalate induces apoptosis through peroxisome proliferators-activated receptor-gamma and ERK 1/2 activation in testis of Sprague-Dawley rats. Ryu JY, etal., J Toxicol Environ Health A. 2007 Aug;70(15-16):1296-303.
49. HPV related VIN: highly proliferative and diminished responsiveness to extracellular signals. Santegoets LA, etal., Int J Cancer. 2007 Aug 15;121(4):759-66.
50. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors. Schmidt BA, etal., Cancer Res. 2001 May 15;61(10):4214-21.
51. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Shai A, etal., Cancer Res. 2007 Feb 15;67(4):1626-35.
52. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Shariat SF, etal., Hum Pathol. 2006 Dec;37(12):1568-76. Epub 2006 Aug 10.
53. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Shariat SF, etal., Urol Oncol. 2007 Nov-Dec;25(6):468-75.
54. The Pezcoller lecture: cancer cell cycles revisited. Sherr CJ Cancer Res. 2000 Jul 15;60(14):3689-95.
55. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice. Shi SY, etal., J Biol Chem. 2017 Mar 3;292(9):3789-3799. doi: 10.1074/jbc.M116.752519. Epub 2017 Jan 18.
56. Enhanced sequential expression of G1/S cyclins during experimental epatocarcinogenesis and tyrosine phosphorylation. Sundarrajan M, etal., J Environ Pathol Toxicol Oncol. 2001;20(3):189-97.
57. Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1. Tamura K, etal., Oncogene 1993 Aug;8(8):2113-8.
58. Different cell cycle regulation of vascular smooth muscle in genetic hypertension. Tanner FC, etal., Hypertension. 2003 Aug;42(2):184-8. Epub 2003 Jul 7.
59. [Effects of cyclin dependent protein kinase inhibitor olomoucine on the microenvironment of axonal regeneration after spinal cord injury: an experiment with rats] Tian DS, etal., Zhonghua Yi Xue Za Zhi. 2006 Apr 4;86(13):901-5.
60. Metformin-induced stimulation of adenosine 5' monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Tosca L, etal., Biol Reprod. 2006 Sep;75(3):342-51. Epub 2006 Jun 7.
61. Impaired hepatic regeneration by ischemic preconditioning in a rat model of small-for-size liver transplantation. Yao A, etal., Transpl Immunol. 2007 Jul;18(1):37-43. Epub 2007 Mar 13.
62. Growth pattern switch of renal cells and expression of cell cycle related proteins at the early stage of diabetic nephropathy. Zhang Y, etal., Biochem Biophys Res Commun. 2007 Nov 9;363(1):159-64. Epub 2007 Aug 31.
63. Inhibited activities in CCAAT/enhancer-binding protein, activating protein-1 and cyclins after hepatectomy in rats with thioacetamide-induced liver cirrhosis. Zhao G, etal., Biochem Biophys Res Commun 2002 Mar 29;292(2):474-81.
64. Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. Zhu Z, etal., Carcinogenesis. 2003 Jul;24(7):1225-31. Epub 2003 May 9.
Additional References at PubMed
PMID:7739547   PMID:7797074   PMID:8673024   PMID:8889548   PMID:9344597   PMID:10500095   PMID:11384971   PMID:11981756   PMID:12124778   PMID:12149264   PMID:12477932   PMID:12722479  
PMID:12941272   PMID:12970171   PMID:12970760   PMID:14985333   PMID:16109376   PMID:18278459   PMID:18359940   PMID:19056892   PMID:19407981   PMID:19723762   PMID:19942931   PMID:21167253  
PMID:21761349   PMID:22713240   PMID:23083510   PMID:23618858   PMID:23771653   PMID:24586195   PMID:24647953   PMID:25175461   PMID:25732226   PMID:37338051  


Genomics

Comparative Map Data
Ccne1
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8199,918,672 - 99,927,986 (-)NCBIGRCr8
mRatBN7.2190,781,947 - 90,791,188 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl190,781,949 - 90,791,101 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx196,177,587 - 96,186,820 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01104,643,512 - 104,652,745 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0197,935,949 - 97,945,186 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0194,485,830 - 94,495,112 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl194,485,832 - 94,494,980 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0195,575,136 - 95,584,387 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4190,568,189 - 90,577,426 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1190,646,304 - 90,655,502 (-)NCBI
Celera185,114,968 - 85,124,206 (-)NCBICelera
RH 3.4 Map1885.7RGD
Cytogenetic Map1q21NCBI
CCNE1
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381929,811,991 - 29,824,312 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1929,811,991 - 29,824,312 (+)EnsemblGRCh38hg38GRCh38
GRCh371930,302,898 - 30,315,219 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361934,994,741 - 35,007,059 (+)NCBINCBI36Build 36hg18NCBI36
Build 341934,995,400 - 35,007,058NCBI
Celera1927,001,121 - 27,013,439 (+)NCBICelera
Cytogenetic Map19q12NCBI
HuRef1926,814,506 - 26,826,846 (+)NCBIHuRef
CHM1_11930,304,072 - 30,316,380 (+)NCBICHM1_1
T2T-CHM13v2.01932,337,722 - 32,350,035 (+)NCBIT2T-CHM13v2.0
Ccne1
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39737,797,409 - 37,806,915 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl737,797,409 - 37,806,959 (-)EnsemblGRCm39 Ensembl
GRCm38738,097,984 - 38,107,490 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl738,097,984 - 38,107,534 (-)EnsemblGRCm38mm10GRCm38
MGSCv37738,883,003 - 38,892,509 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36737,806,744 - 37,816,090 (-)NCBIMGSCv36mm8
Celera733,255,165 - 33,271,131 (-)NCBICelera
Cytogenetic Map7B3NCBI
cM Map725.35NCBI
Ccne1
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554687,803,346 - 7,814,872 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554687,803,610 - 7,814,872 (-)NCBIChiLan1.0ChiLan1.0
CCNE1
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v22035,791,482 - 35,803,832 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11937,788,541 - 37,800,858 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01926,739,285 - 26,751,630 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11935,497,576 - 35,509,289 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1935,496,700 - 35,510,295 (+)Ensemblpanpan1.1panPan2
CCNE1
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11121,688,622 - 121,697,533 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1121,688,796 - 121,697,649 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1121,057,141 - 121,067,963 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01122,317,344 - 122,328,414 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1122,317,344 - 122,327,556 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11121,897,115 - 121,908,170 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01121,503,639 - 121,514,505 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01122,568,738 - 122,579,545 (-)NCBIUU_Cfam_GSD_1.0
Ccne1
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_0244093496,098,056 - 6,108,393 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365705,536,672 - 5,548,008 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_0049365705,536,817 - 5,547,880 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
CCNE1
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl639,919,624 - 39,933,363 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1639,919,541 - 39,933,224 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2635,242,127 - 35,255,298 (+)NCBISscrofa10.2Sscrofa10.2susScr3
CCNE1
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1624,879,923 - 24,888,985 (+)NCBIChlSab1.1ChlSab1.1chlSab2
Vero_WHO_p1.0NW_0236660732,422,215 - 2,433,635 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Ccne1
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247944,957,178 - 4,967,140 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247944,957,156 - 4,967,058 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Ccne1
15 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:339
Count of miRNA genes:194
Interacting mature miRNAs:233
Transcripts:ENSRNOT00000020014
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
2313059Bss55Bone structure and strength QTL 553.20.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
631688Hcas2Hepatocarcinoma susceptibility QTL 230.0001liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)15925874115540829Rat
1578649Bmd8Bone mineral density QTL 84.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)14939317294393172Rat
1582234Gluco18Glucose level QTL 183.40.0003blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)178479925123479925Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)149393289199050459Rat
1358359Sradr1Stress Responsive Adrenal Weight QTL 14.74adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)130882023123479925Rat
1578780Cm52Cardiac mass QTL 523.30.0001heart mass (VT:0007028)heart wet weight (CMO:0000069)181591954219808434Rat
1578654Bss10Bone structure and strength QTL 104femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)149393172159356837Rat
2300324Fetw1Fetal weight QTL 112.10.005fetal growth trait (VT:0004201)fetal body weight (CMO:0002080)185424647100358001Rat
1300121Hrtrt1Heart rate QTL 13.7heart pumping trait (VT:2000009)heart rate (CMO:0000002)165789093115540829Rat
7421628Bp361Blood pressure QTL 3610.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)166023617118608521Rat
631495Bp96Blood pressure QTL 964.52arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)122340647102268831Rat
70225Bp58Blood pressure QTL 583.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132356093162846471Rat
2298545Neuinf8Neuroinflammation QTL 84.6nervous system integrity trait (VT:0010566)spinal cord beta-2 microglobulin mRNA level (CMO:0002125)157336763151090257Rat
2313072Bss53Bone structure and strength QTL 534.30.0001tibia length (VT:0004357)tibia length (CMO:0000450)143284731118944897Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132737458199368955Rat
2313078Bss54Bone structure and strength QTL 543.50.0001tibia area (VT:1000281)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
1302788Scl19Serum cholesterol QTL 194.60.001blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)190532338123479925Rat
1549903Bp267Blood pressure QTL 267arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)177876254106047988Rat
2313083Bmd74Bone mineral density QTL 7440.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)182174743118944897Rat
2313402Anxrr24Anxiety related response QTL 24aggression-related behavior trait (VT:0015014)tameness/aggressiveness composite score (CMO:0002136)148963584144267916Rat
4889494Scort2Serum corticosterone level QTL 24.2blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)180592172125592172Rat
61342Bp27Blood pressure QTL 273.40.0006arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)15673266898773277Rat
61344Bp29Blood pressure QTL 297.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)178350581123350581Rat
724521Uae1Urinary albumin excretion QTL 13.80.0001urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)190508614173018436Rat
1358902Bw47Body weight QTL 471.67body mass (VT:0001259)body weight (CMO:0000012)190508614180359386Rat
1358192Ept13Estrogen-induced pituitary tumorigenesis QTL 133.4pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)177494165122494165Rat
2313094Bss58Bone structure and strength QTL 583.70.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)143284731118944897Rat
2300164Bmd44Bone mineral density QTL 445.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)156949932101949932Rat
2313099Bss56Bone structure and strength QTL 562.40.0001tibia size trait (VT:0100001)tibia midshaft endosteal cross-sectional area (CMO:0001716)143284731118944897Rat
2313098Bmd70Bone mineral density QTL 703.60.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)143284731118944897Rat
1300153Bp171Blood pressure QTL 1713.37arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)190664883143200202Rat
738022Anxrr13Anxiety related response QTL 134.60.00039locomotor behavior trait (VT:0001392)number of 20 x 20 cm floor squares crossed into, out of or within a discrete space in an experimental apparatus (CMO:0001514)183547917128547917Rat
10054135Gmadr2Adrenal mass QTL 21.970.0129adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)177857876122857876Rat
152025249Scl82Serum cholesterol level QTL 824.77blood cholesterol amount (VT:0000180)15034351099980958Rat
7411712Strs4Sensitivity to stroke QTL 48.7cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)178430536123430536Rat
2313051Bss57Bone structure and strength QTL 573.70.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)143284731118944897Rat
61433Cia2Collagen induced arthritis QTL 25joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)17843075491209302Rat
724529Cm16Cardiac mass QTL 162.7heart mass (VT:0007028)calculated heart weight (CMO:0000073)187580395150700247Rat

Markers in Region
D1Bda17  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2190,782,249 - 90,782,469 (+)MAPPERmRatBN7.2
Rnor_6.0194,486,133 - 94,486,352NCBIRnor6.0
Rnor_5.0195,575,439 - 95,575,658UniSTSRnor5.0
RGSC_v3.4190,568,492 - 90,568,711UniSTSRGSC3.4
Celera185,115,271 - 85,115,490UniSTS
Cytogenetic Map1q22UniSTS
RH94399  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2190,781,980 - 90,782,135 (+)MAPPERmRatBN7.2
Rnor_6.0194,485,864 - 94,486,018NCBIRnor6.0
Rnor_5.0195,575,170 - 95,575,324UniSTSRnor5.0
RGSC_v3.4190,568,223 - 90,568,377UniSTSRGSC3.4
Celera185,115,002 - 85,115,156UniSTS
RH 3.4 Map1885.7UniSTS
Cytogenetic Map1q22UniSTS


Expression

RNA-SEQ Expression

alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
nervous system
renal system
reproductive system
respiratory system
9 11 49 113 91 90 59 25 59 6 218 97 93 45 60 31

Sequence


Ensembl Acc Id: ENSRNOT00000020014   ⟹   ENSRNOP00000020014
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl190,781,949 - 90,791,101 (-)Ensembl
Rnor_6.0 Ensembl194,485,832 - 94,494,980 (-)Ensembl
RefSeq Acc Id: NM_001100821   ⟹   NP_001094291
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8199,918,672 - 99,927,909 (-)NCBI
mRatBN7.2190,781,947 - 90,791,188 (-)NCBI
Rnor_6.0194,485,830 - 94,495,067 (-)NCBI
Rnor_5.0195,575,136 - 95,584,387 (-)NCBI
RGSC_v3.4190,568,189 - 90,577,426 (-)RGD
Celera185,114,968 - 85,124,206 (-)RGD
Sequence:
RefSeq Acc Id: XM_006228904   ⟹   XP_006228966
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8199,918,672 - 99,927,986 (-)NCBI
mRatBN7.2190,781,947 - 90,791,101 (-)NCBI
Rnor_6.0194,485,830 - 94,495,112 (-)NCBI
Rnor_5.0195,575,136 - 95,584,387 (-)NCBI
Sequence:
Protein Sequences
Protein RefSeqs NP_001094291 (Get FASTA)   NCBI Sequence Viewer  
  XP_006228966 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAI62008 (Get FASTA)   NCBI Sequence Viewer  
  BAA09640 (Get FASTA)   NCBI Sequence Viewer  
  EDM07591 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSRNOP00000020014.4
GenBank Protein P39949 (Get FASTA)   NCBI Sequence Viewer  
RefSeq Acc Id: NP_001094291   ⟸   NM_001100821
- UniProtKB: P39949 (UniProtKB/Swiss-Prot),   O09138 (UniProtKB/Swiss-Prot),   B1WC54 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: XP_006228966   ⟸   XM_006228904
- Peptide Label: isoform X1
- UniProtKB: P39949 (UniProtKB/Swiss-Prot),   O09138 (UniProtKB/Swiss-Prot),   B1WC54 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000020014   ⟸   ENSRNOT00000020014
Protein Domains
Cyclin C-terminal   Cyclin-like

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P39949-F1-model_v2 AlphaFold P39949 1-411 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13689977
Promoter ID:EPDNEW_R502
Type:multiple initiation site
Name:Ccne1_1
Description:cyclin E1
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0194,495,077 - 94,495,137EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2294 AgrOrtholog
BioCyc Gene G2FUF-59942 BioCyc
Ensembl Genes ENSRNOG00000014786 Ensembl, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000020014.5 UniProtKB/TrEMBL
Gene3D-CATH Cyclin-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:9090267 IMAGE-MGC_LOAD
InterPro Cyclin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin-like_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_A/B-like UniProtKB/TrEMBL
  Cyclin_C-dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclins_cyclin-box UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:25729 UniProtKB/TrEMBL
MGC_CLONE MGC:187868 IMAGE-MGC_LOAD
NCBI Gene 25729 ENTREZGENE
PANTHER PTHR10177 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR10177:SF71 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Cyclin_C UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_N UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Ccne1 PhenoGen
PIRSF Cyclin_A_B_D_E UniProtKB/TrEMBL
PROSITE CYCLINS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000014786 RatGTEx
SMART CYCLIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyclin_C UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF47954 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A6JAE3_RAT UniProtKB/TrEMBL
  B1WC54 ENTREZGENE, UniProtKB/TrEMBL
  CCNE1_RAT UniProtKB/Swiss-Prot
  O09138 ENTREZGENE
  P39949 ENTREZGENE
UniProt Secondary O09138 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2008-01-25   cyclin E1  Ccne1  cyclin E  Name updated to reflect Human and Mouse nomenclature 1299863 APPROVED
2004-09-10 Ccne1  cyclin E  Ccne    Symbol and Name updated 1299863 APPROVED
2002-06-10 Ccne  Cyclin E      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_disease expression is lower in the thioacetamide-induced cirrhosis after partial hepatectomy 70813
gene_process can malignantly transform primary rat embryo fibroblasts in cooperation with constitutively active Ha-Ras and is involved in the development of methyl-nitroso-urea-induced T-cell lymphomas 68222
gene_process activates Cdk2 and also binds p27Kip1 68222